uracil has been researched along with Cardiovascular Stroke in 19 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
| Excerpt | Relevance | Reference |
|---|---|---|
| " The EXAMINE trial confirmed noninferiority of the dipeptidyl dipeptidase 4 inhibitor alogliptin to placebo on major adverse cardiac event rates in a post-acute coronary syndrome (ACS) T2DM population." | 9.22 | Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care tria ( Bakris, GL; Cannon, CP; Cushman, WC; Kupfer, S; Liu, Y; Mehta, CR; Menon, V; Shimada, YJ; White, WB; Wilson, C; Zannad, F, 2016) |
| "In patients with type 2 diabetes and recent acute coronary syndromes, alogliptin did not increase the risk of heart failure outcomes." | 9.20 | Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. ( Bakris, GL; Cannon, CP; Cushman, WC; Fleck, PR; Kupfer, S; Lam, H; Mehta, CR; Menon, V; Perez, AT; White, WB; Wilson, C; Zannad, F, 2015) |
| "The effect of a series of drugs (retabolil, strophanthin, retabolil with strophanthin, retabolil with panangin , methyluracil with panangin ) on protein metabolism was investigated in 246 patients with acute myocardial infarction." | 7.67 | [Correction of protein metabolism in myocardial infarction according to the results of radionuclide studies with 131-albumin during during treatment with a number of drugs (retabolyl, methyluracil, panangin, strophanthin) and combinations of them]. ( Anisimova, LV; Barbakova, AA; Leshchinskiĭ, LA; Trusov, VV, 1984) |
| " The EXAMINE trial confirmed noninferiority of the dipeptidyl dipeptidase 4 inhibitor alogliptin to placebo on major adverse cardiac event rates in a post-acute coronary syndrome (ACS) T2DM population." | 5.22 | Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care tria ( Bakris, GL; Cannon, CP; Cushman, WC; Kupfer, S; Liu, Y; Mehta, CR; Menon, V; Shimada, YJ; White, WB; Wilson, C; Zannad, F, 2016) |
| "In patients with type 2 diabetes and recent acute coronary syndromes, alogliptin did not increase the risk of heart failure outcomes." | 5.20 | Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. ( Bakris, GL; Cannon, CP; Cushman, WC; Fleck, PR; Kupfer, S; Lam, H; Mehta, CR; Menon, V; Perez, AT; White, WB; Wilson, C; Zannad, F, 2015) |
| "We randomly assigned patients with type 2 diabetes and either an acute myocardial infarction or unstable angina requiring hospitalization within the previous 15 to 90 days to receive alogliptin or placebo in addition to existing antihyperglycemic and cardiovascular drug therapy." | 5.17 | Alogliptin after acute coronary syndrome in patients with type 2 diabetes. ( Bakris, GL; Bergenstal, RM; Cannon, CP; Cushman, WC; Fleck, PR; Heller, SR; Kupfer, S; Mehta, CR; Nissen, SE; Perez, AT; White, WB; Wilson, C; Zannad, F, 2013) |
| "The effect of a series of drugs (retabolil, strophanthin, retabolil with strophanthin, retabolil with panangin , methyluracil with panangin ) on protein metabolism was investigated in 246 patients with acute myocardial infarction." | 3.67 | [Correction of protein metabolism in myocardial infarction according to the results of radionuclide studies with 131-albumin during during treatment with a number of drugs (retabolyl, methyluracil, panangin, strophanthin) and combinations of them]. ( Anisimova, LV; Barbakova, AA; Leshchinskiĭ, LA; Trusov, VV, 1984) |
| "Alogliptin did not increase the risk of either first or recurrent CV events when compared with placebo in patients with T2DM and recent acute coronary syndrome." | 2.87 | Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome. ( Bergenstal, RM; Cannon, CP; Cavender, MA; Cushman, WC; Heller, S; Liu, Y; Massaro, JM; Mehta, CR; White, WB; Zannad, F, 2018) |
| "Early after an ACS, patients with type 2 diabetes mellitus experience a significant burden of HF events and recurrent ACS." | 2.87 | Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial. ( Bakris, GL; Cannon, CP; Cushman, WC; Liu, Y; Sharma, A; White, WB; Zannad, F, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (10.53) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (78.95) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Ferreira, JP | 2 |
| Sharma, A | 3 |
| Mehta, C | 3 |
| Bakris, G | 2 |
| Rossignol, P | 2 |
| White, WB | 8 |
| Zannad, F | 9 |
| Elharram, M | 1 |
| White, W | 1 |
| Hwang, YC | 1 |
| Morrow, DA | 1 |
| Cannon, CP | 6 |
| Liu, Y | 4 |
| Bergenstal, R | 1 |
| Heller, S | 2 |
| Cushman, W | 1 |
| Bakris, GL | 5 |
| Cavender, MA | 1 |
| Massaro, JM | 1 |
| Bergenstal, RM | 2 |
| Mehta, CR | 4 |
| Cushman, WC | 5 |
| Heller, SR | 1 |
| Nissen, SE | 1 |
| Perez, AT | 2 |
| Fleck, PR | 2 |
| Kupfer, S | 3 |
| Wilson, C | 3 |
| Lim, GB | 1 |
| Greenhill, C | 1 |
| Standl, E | 1 |
| Doggrell, SA | 1 |
| Dimmitt, SB | 1 |
| Gallwitz, B | 1 |
| Nitschmann, S | 1 |
| Violini, R | 1 |
| Vigili de Kreutzenberg, S | 1 |
| Menon, V | 2 |
| Lam, H | 1 |
| Dicembrini, I | 1 |
| Mannucci, E | 1 |
| Derosa, G | 1 |
| Maffioli, P | 1 |
| Shimada, YJ | 1 |
| Leshchinskiĭ, LA | 1 |
| Trusov, VV | 1 |
| Anisimova, LV | 1 |
| Barbakova, AA | 1 |
| Brusilovskii, ES | 1 |
| Grokhptpva, SG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome[NCT00968708] | Phase 3 | 5,380 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Primary Major Adverse Cardiac Events were defined as a composite of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke; these events were adjudicated by an independent cardiovascular endpoints committee. (NCT00968708)
Timeframe: From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 11.8 |
| Alogliptin | 11.3 |
Secondary MACE composite consisted of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or urgent revascularization due to unstable angina; these events were adjudicated by an independent cardiovascular endpoint committee. (NCT00968708)
Timeframe: From randomization until the adjudication cut-of date of May 31 2013 (maximum time on study was 41 months).
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 13.4 |
| Alogliptin | 12.7 |
1 review available for uracil and Cardiovascular Stroke
| Article | Year |
|---|---|
Risk of myocardial infarction in trials with Dipeptidyl Peptidase-4 inhibitors: Is duration of study a real issue?
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Incid | 2015 |
9 trials available for uracil and Cardiovascular Stroke
| Article | Year |
|---|---|
Multi-proteomic approach to predict specific cardiovascular events in patients with diabetes and myocardial infarction: findings from the EXAMINE trial.
Topics: Biomarkers; Cause of Death; Comorbidity; Diabetes Mellitus, Type 2; Female; Fibroblast Growth Factor | 2021 |
Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus.
Topics: Acute Coronary Syndrome; Comorbidity; Diabetes Mellitus, Type 2; Evidence-Based Practice; Female; He | 2020 |
High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial.
Topics: Acute Coronary Syndrome; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic A | 2018 |
Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female | 2018 |
Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial.
Topics: Acute Coronary Syndrome; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double | 2018 |
Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
Topics: Aged; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV | 2013 |
[The EXAMINE study].
Topics: Administration, Oral; Angina, Unstable; Biomarkers; Diabetes Mellitus, Type 2; Double-Blind Method; | 2014 |
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathie | 2015 |
Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care tria
Topics: Acute Coronary Syndrome; Aged; Diabetes Mellitus, Type 2; Female; Hospitalization; Humans; Hypoglyce | 2016 |
9 other studies available for uracil and Cardiovascular Stroke
| Article | Year |
|---|---|
Diabetes: Cardiovascular safety of 'gliptin' therapy.
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipept | 2013 |
Pharmacotherapy: Cardiovascular safety of antihyperglycaemic drugs in patients with type 2 diabetes mellitus.
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipept | 2013 |
Saxagliptin, alogliptin, and cardiovascular outcomes.
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipept | 2014 |
Saxagliptin, alogliptin, and cardiovascular outcomes.
Topics: Angina, Unstable; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hyp | 2014 |
Gliptins - do they increase cardiovascular risk or benefit?
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipept | 2014 |
[New antihyperglycemic drugs. Examination of cardiovascular outcomes with alogliptin versus standard of care (EXAMINE) and saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR
Topics: Adamantane; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipept | 2014 |
Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Angina, Unstable; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibi | 2016 |
[Correction of protein metabolism in myocardial infarction according to the results of radionuclide studies with 131-albumin during during treatment with a number of drugs (retabolyl, methyluracil, panangin, strophanthin) and combinations of them].
Topics: Adult; Aged; Anabolic Agents; Drug Therapy, Combination; Humans; Middle Aged; Myocardial Infarction; | 1984 |
[Drug induced allergic myocardites].
Topics: Acute Disease; Antithyroid Agents; Carbonates; Diagnosis, Differential; Drug Hypersensitivity; Gold; | 1969 |